Epinephrine Lidocaine HCL recall — Class II (D-0535-2025) · pharmaranks
Class IICompleted
Epinephrine Lidocaine HCL recall
FDA recall D-0535-2025 · initiated Jul 9, 2025
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Sub-Potent Drug: Subpotent assay results during stability testing.
Details
Product
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Recalling company
Imprimis NJOF, LLC
Classification
Class II
Status
Completed
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jul 9, 2025
FDA report date
Jul 30, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.